Active substance
Stibogluconate
- SFDA 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PENTOSTAM | 100 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 453.75 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by MAH · Not Marketed |
| PENTOSTAM | 100 mg/ml | Solution for injection · Intravenous use | 10 Vial | SAR 106.90 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by MAH · Not Marketed |
WHO WHO Model List of Essential Medicines (2025)
- 6.5.2. Antileishmaniasis medicines · core
Visceral leishmaniasis; Mucocutaneous leishmaniasis; Cutaneous leishmaniasis
Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.